Inclusion Criteria:  Signed written informed consent Men or women aged 18 years and older Diagnosis of Systemic sclerosis, as defined by 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc. Baseline T score of 45 on the PROMIS-Fatigue scale. Steady daily doses and any immunosuppressive medication, vasodilators, antidepressants and anxiolytic use for 4 weeks prior to baseline. Currently owns and operates an iOS or Android smart phone regularly Ability to comply with the clinical visits schedule and the study-related procedures. Subjects who have struggled with symptoms of SSc (specifically fatigue and Raynauds) who have not received adequate symptom relief from prior treatment attempts (treatment-resistant) will be prioritized.  Exclusion Criteria:  Medical and surgical history  Major surgery within 8 weeks prior to screening Participants with an active malignancy. End-stage renal disease with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2 (MDRD formula) or on dialysis at the screening visit Hepatic insufficiency as defined by the Child-Pugh criteria Hospitalization for any reason within four weeks of the study baseline visit. History of sympathectomy or stellate ganglion block Significant interstitial lung disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin) ≤ 40% of predicted Pulmonary hypertension with change in medications in the preceding four weeks Actively prescribed standing doses of beta-blockers. Actively prescribed standing doses of sedatives, hypnotics, opioids, or benzodiazepines. Active or unstable psychotic disorder requiring current prescriptions of standing doses of antipsychotic medications Active suicidal/homicidal ideation or a suicide or homicide attempt in the past year. Pregnant or breastfeeding women Other • Any other condition or therapy that would make the participant unsuitable for this study and will not allow participation for the full planned study period